SAN DIEGO—Metabolic syndrome (MetS) in patients with stage 3 and 4 chronic kidney disease (CKD) is associated with an increased risk of development of end-stage renal disease (ESRD), according to a study presented at Kidney Week 2012.

The study by Sankar D. Navaneethan, MD, MPH, of Cleveland Clinic, and colleagues included 25,868 patients with stage 3 and 4 CKD. Of these, 15,605 (60%) had MetS. During a mean follow-up of 2.3 years, 3,345 participants died before reaching ESRD and 481 reached ESRD. Overall, MetS was associated with a 30% increased risk of ESRD while it was not associated with death among those with stage 3 and stage 4 kidney disease.

For the individual components of metabolic syndrome, elevated triglycerides, hypertension and impaired glucose metabolism were associated with a 7%, 67%, and 83% increased risk for ESRD, respectively, compared with the absence of these components.

Continue Reading

“Our study findings reveal the higher prevalence of metabolic syndrome in patients with CKD,” Dr. Navaneethan told Renal & Urology News. “Metabolic syndrome is independently associated with end-stage renal disease. Whether interventions such as lifestyle modifications can improve the risk associated with metabolic syndrome on kidney disease progression merits further study.” Additional long-term studies examining the relationship between metabolic syndrome and death in this population are also warranted, he said.